42 completed, 15 recruiting, 14 active not recruiting, 10 withdrawn. 60 Phase 2, 31 Phase 1, 7 Phase 3, 4 Early Phase 1, 2 Not applicable.
Follow Paclitaxel Albumin-Stabilized Nanoparticle Formulation: new trials by email Literature Review of Paclitaxel Albumin-Stabilized Nanoparticle Formulation trials Research Report on Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial Biospecimen Collection, Computed Tomography, Electronic Health Record Review - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Not yet recruiting | Northwestern University | 125 | 2027-02-03 | 2026-08-06 |
| DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging - Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 50 | 2026-10-01 | 2026-10-05 |
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations Biospecimen Collection, Computed Tomography, Fluorouracil - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 94 | 2026-05-13 | 2026-05-22 |
| BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma | Phase 2 | Recruiting | Mayo Clinic | 43 | 2025-12-12 | 2026-10-02 |
| Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases Biopsy, Biospecimen Collection, Computed Tomography - Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Gastric Adenocarcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 30 | 2025-10-29 | 2025-11-10 |
| Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Capecitabine - Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 356 | 2025-08-21 | 2026-08-25 |
| Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer Biopsy, Biospecimen Collection, Cisplatin - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma | Phase 2 | Recruiting | Georgetown University | 36 | 2024-08-06 | 2026-09-30 |
| Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma Onvansertib, Gemcitabine, Nab-paclitaxel - Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2024-08-01 | 2024-07-19 | |
| Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial Carboplatin, Computed Tomography, Magnetic Resonance Imaging - Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 | Phase 3 | Recruiting | National Cancer Institute (NCI) | 304 | 2024-07-19 | 2026-10-22 |
| Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial Cisplatin, Gemcitabine Hydrochloride, Infigratinib Phosphate - Resectable Intrahepatic Cholangiocarcinoma, Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8 | Phase 2 | Withdrawn | Emory University | 2024-03-01 | 2023-12-26 | |
| Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis Cisplatin, Hyperthermic Intraperitoneal Chemotherapy, Nab-paclitaxel - Metastatic Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v8 | Phase 2 | Active not recruiting | Mayo Clinic | 40 | 2024-02-15 | 2026-10-15 |
| Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer Carboplatin, Cisplatin, Computed Tomography - Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 474 | 2023-07-12 | 2026-08-17 |
| CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8 | Phase 1 | Suspended | National Cancer Institute (NCI) | 43 | 2023-06-12 | 2026-09-09 |
| Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 57 | 2023-05-18 | 2026-09-30 |
| Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer Biospecimen Collection, Carboplatin, Computed Tomography - Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 25 | 2023-05-09 | 2024-10-17 |
| New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study Cisplatin, Fluorouracil, Gemcitabine - Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2023-04-18 | 2026-05-04 | |
| SMMART Adaptive Clinical Treatment (ACT) Trial Alectinib, Alpelisib, Anastrozole - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2023-01-30 | 2024-01-23 | |
| Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases Cisplatin, Gemcitabine, Nab-paclitaxel - Distal Bile Duct Adenocarcinoma, Gallbladder Carcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 12 | 2022-09-19 | 2026-08-03 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Atezolizumab, Cabozantinib S-malate, Nab-paclitaxel - Advanced Breast Carcinoma, Advanced Endometrial Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 43 | 2022-04-29 | 2026-07-16 |
| Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer Gemcitabine Hydrochloride, Nab-paclitaxel, Fluorouracil - Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Flemming Forsberg | 120 | 2021-12-06 | 2025-11-04 |
Showing 20 of 95. Sign in to see all of them.
Breast Neoplasms (26) · Pancreatic Neoplasms (22) · Carcinoma, Non-Small-Cell Lung (12) · Lung Neoplasms (12) · Breast Neoplasms, Male (7) · Triple Negative Breast Neoplasms (7) · Cholangiocarcinoma (5) · Gallbladder Neoplasms (5) · Inflammatory Breast Neoplasms (5) · Ovarian Neoplasms (5) · Carcinoma, Ovarian Epithelial (4) · Fallopian Tube Neoplasms (4) · Melanoma (4) · Prostatic Neoplasms (4) · Stomach Neoplasms (4)
M.D. Anderson Cancer Center (10) · City of Hope Medical Center (9) · National Cancer Institute (NCI) (7) · Mayo Clinic (6) · University of Washington (5) · Alliance for Clinical Trials in Oncology (4) · OHSU Knight Cancer Institute (4) · SWOG Cancer Research Network (4) · University of Chicago (4) · ECOG-ACRIN Cancer Research Group (2) · Emory University (2) · Gynecologic Oncology Group (2) · Memorial Sloan Kettering Cancer Center (2) · NRG Oncology (2) · Northwestern University (2)
United States (88) · Puerto Rico (3) · Canada (2) · China (1) · Norway (1) · Singapore (1)
Svetomir Markovic, MD, PhD (2) · A P Chen (1) · Ana C Garrido-Castro (1) · Anita Aggarwal, DO, PhD (1) · Anthony El-Khoueiry (1) · Anthony Shields (1) · Antoni Ribas, MD (1) · Apostolia M Tsimberidou (1) · Arkadiusz Dudek, MD (1) · Barbara Goff (1) · Brandon G Smaglo (1) · Brandon G Smaglo, MD (1) · Brett L Ecker, MD (1) · Charles B Simone (1)
PMID 18235124, PMID 19706807, PMID 19877111, PMID 21359953, PMID 21461889, PMID 21472717, PMID 22307213, PMID 22915053, PMID 24013936, PMID 25476537, PMID 25492923, PMID 25845992, PMID 26056183, PMID 26123189, PMID 28114604, PMID 28620884, PMID 28797458, PMID 28918548, PMID 28939558, PMID 30481287, PMID 30623229, PMID 30998813, PMID 31147146, PMID 31319977, PMID 32740235, PMID 32939319, PMID 33475684, PMID 33720068, PMID 34616010, PMID 34980020, PMID 35863672, PMID 35945244, PMID 36427020, PMID 36963200, PMID 37061619, PMID 37596449, PMID 38445914, PMID 39169033, PMID 39263892, PMID 39446377, PMID 39615497, PMID 39671534, PMID 39730001, PMID 39863139, PMID 41133726, PMID 42623567
P30CA033572 (4), U10CA180820 (4), P30CA015083 (3), U10CA180888 (3), P30CA014599 (2), P30CA015704 (2), P30CA068485 (2), P30CA138292 (2), U10CA027469 (2), U10CA180868 (2), P30CA006973 (1), P30CA012197 (1), P30CA014089 (1), P30CA016056 (1), P30CA022453 (1)